---
title: "Analyst Reiterates Buy on Rigel as VEPPANU Acquisition Expands Portfolio; Price Target Maintained at $57"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286143464.md"
description: "Analyst Joseph Pantginis from H.C. Wainwright has reiterated a Buy rating on Rigel Pharmaceuticals, maintaining a price target of $57. The rating is based on Rigel's acquisition of VEPPANU, an FDA-approved therapy for advanced breast cancer, which expands its portfolio to four approved products. Pantginis believes this asset will enhance physician adoption and patient retention. He views the focused ESR1-mutated market as impactful for Rigel, especially with management's plans to leverage existing infrastructure. Citi also maintains a Buy rating with a $69 price target."
datetime: "2026-05-12T17:15:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286143464.md)
  - [en](https://longbridge.com/en/news/286143464.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286143464.md)
---

# Analyst Reiterates Buy on Rigel as VEPPANU Acquisition Expands Portfolio; Price Target Maintained at $57

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel and keeping the price target at $57.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Joseph Pantginis has given his Buy rating due to a combination of factors, chiefly Rigel’s acquisition of global rights to VEPPANU, an FDA-approved, de-risked PROTAC therapy for a defined subset of advanced breast cancer patients. He views this asset as a strong commercial addition that expands Rigel’s portfolio to four approved products, supported by a differentiated mechanism and a favorable tolerability profile that could drive physician adoption and patient retention.

Pantginis also believes the focused ESR1-mutated market, while narrower than the broader ER+/HER2- setting, can still be meaningfully impactful for a company of Rigel’s size, especially as management plans to leverage its existing commercial and medical infrastructure for launch. With Pfizer and Arvinas retaining responsibility for ongoing trials and Rigel’s financial commitments capped and milestone-based, he sees an attractive risk-reward setup and therefore reiterates his Buy rating with an unchanged $57 price target.

In another report released on May 7, Citi also maintained a Buy rating on the stock with a $69.00 price target.

### Related Stocks

- [RIGL.US](https://longbridge.com/en/quote/RIGL.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [These Analysts Increase Their Forecasts On Arvinas After Q1 Results](https://longbridge.com/en/news/286300592.md)
- [Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target](https://longbridge.com/en/news/286287214.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Do Wall Street Analysts Like Equity Residential Stock?](https://longbridge.com/en/news/286806057.md)